An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy
2016/05/24 by Christina M. Dieli‐Conwright, Louise Wong, Sarah Waliany +4 · 26 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Cancer Risks and Factors #Metabolism, Diabetes, and Cancer #Cancer, Lipids, and Metabolism
paper · doi:10.1002/cncr.30104
Abstract
BACKGROUND: The authors sought to determine the effect of chemotherapy on the development of metabolic syndrome (MetS) in premenopausal and postmenopausal women undergoing (neo)adjuvant therapy for early-stage breast cancer. METHODS: A total of 86 women with early-stage (AJCC stage I-III) breast cancer who were free from clinically diagnosed MetS (defined as 3 of 5 components of MetS) were prospectively tested for the presence of the 5 components of MetS within 1 week before initiating and after completing (neo)adjuvant chemotherapy. The 5 components of MetS measured were waist circumference; blood pressure; and fasting levels of blood glucose, triglycerides, and high-density lipoprotein cholesterol. Anthropometrics (body weight, percentage body fat, fat mass), lipid profile (total cholesterol, low-density lipoprotein cholesterol), glucose metabolism (insulin, homeostatic model assessment of insulin resistance, glycated hemoglobin), and inflammation (C-reactive protein) also were examined before initiating and after completing treatment. RESULTS: The current study included 46 premenopausal and 40 postmenopausal women. All individual MetS components and the overall MetS score were found to be statistically significantly increased (P<.01) after chemotherapy. Body weight, percentage body fat, fat mass, lipids, glucose metabolism, and inflammation also were found to be statistically significantly increased (P<.01). CONCLUSIONS: A 12-week to 18-week course of chemotherapy appears to statistically significantly increase MetS and related anthropometrics, biomarkers of glucose metabolism, and inflammation in patients with early-stage breast cancer with no preexisting MetS. Lifestyle interventions such as diet and exercise may be preventive approaches for use during chemotherapy to reduce the onset of MetS in patients with breast cancer. Cancer 2016. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. Cancer 2016;122:2646-2653. © 2016 American Cancer Society.
Cited by
- A Dietitian Survivorship Clinic for Early-Stage Breast and Gynaecologic Cancer Survivors: A Dietetic Protocol for the Linking You to Support and Advice (LYSA) Randomised Controlled Trial
- Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment. [europepmc]
- Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment. [europepmc]
- Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-A systematic review. [europepmc]
- Key metabolic parameters change significantly in early breast cancer survivors: an explorative PILOT study. [europepmc]
- Opportunities for cannabis in supportive care in cancer. [europepmc]
- Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies. [europepmc]
- Metabolic Health, Insulin, and Breast Cancer: Why Oncologists Should Care About Insulin. [europepmc]
- Adjuvant chemotherapy-associated lipid changes in breast cancer patients: A real-word retrospective analysis. [europepmc]
- Implications of metabolism-driven myeloid dysfunctions in cancer therapy. [europepmc]
- The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies. [europepmc]
- Dynamic Changes of Blood Lipids in Breast Cancer Patients After (Neo)adjuvant Chemotherapy: A Retrospective Observational Study. [europepmc]
- Brown adipose tissue is associated with cardiometabolic health. [europepmc]
- Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis. [europepmc]
- Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women's Health Initiative (WHI) randomised trial. [europepmc]
- Impact of cholesterol-pathways on breast cancer development, a metabolic landscape. [europepmc]
- ¡Mi Vida Saludable! A randomized, controlled, 2 × 2 factorial trial of a diet and physical activity intervention among Latina breast cancer survivors: Study design and methods. [europepmc]
- Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study. [europepmc]
- Time-Restricted Eating: A Novel and Simple Dietary Intervention for Primary and Secondary Prevention of Breast Cancer and Cardiovascular Disease. [europepmc]
- Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. [europepmc]
- Metabolic syndrome and breast cancer survivors: a follow-up analysis after completion of chemotherapy. [europepmc]
- RETRACTED: Metformin and Breast Cancer: Where Are We Now? [europepmc]
- Longitudinal Changes in Skeletal Muscle Metabolism, Oxygen Uptake, and Myosteatosis During Cardiotoxic Treatment for Early-Stage Breast Cancer. [europepmc]
- Time-restricted Eating to Address Cancer-related Fatigue among Cancer Survivors: A Single-arm Pilot Study. [europepmc]
- Barriers and Facilitators to Adherence to a Mediterranean Diet Intervention during Chemotherapy Treatment: A Qualitative Analysis. [europepmc]
- The Challenges of Treating Patients with Breast Cancer and Obesity. [europepmc]
Related